Clinical Context
The GLP-1 receptor agonist class, of which semaglutide is a prominent member, works by mimicking the incretin hormone GLP-1 — naturally released after eating. Semaglutide's once-weekly dosing achieved via structural modifications to the GLP-1 peptide backbone gives it a clinical half-life of approximately seven days. This sustained receptor engagement translates into consistent appetite suppression, improved glucose-dependent insulin secretion, and slowed gastric emptying. Because it acts centrally (in the hypothalamus and brainstem), it modulates energy homeostasis in ways that caloric restriction alone cannot replicate.
Key Studies & References
STEP 1 Trial (NEJM, 2021)
A 68-week double-blind, placebo-controlled RCT in 1,961 adults with BMI ≥30 (or ≥27 with comorbidities). Semaglutide 2.4 mg weekly produced mean body weight reduction of 14.9% versus 2.4% with placebo. 86.4% of semaglutide participants achieved ≥5% weight loss.
STEP 4 Trial (JAMA, 2021)
Demonstrated the necessity of continued treatment. Participants who had achieved weight loss and were then switched to placebo regained most lost weight, while those continuing semaglutide maintained and extended their reduction — establishing the chronic disease model of treatment.
SELECT Cardiovascular Outcomes Trial (NEJM, 2023)
A landmark trial in 17,604 adults with established cardiovascular disease and overweight or obesity (without diabetes). Semaglutide produced a 20% relative risk reduction in major adverse cardiovascular events (MACE) over a median 3.3-year follow-up, expanding the clinical rationale beyond weight loss alone.
FDA Prescribing Information — Wegovy & Ozempic
Regulatory documentation confirms mechanism, approved indications, contraindications (MTC history, MEN 2, pregnancy), dose titration schedule, and long-term safety monitoring requirements.
Evidence Quality: High
Semaglutide's evidence base is exceptional for a metabolic agent: multiple large-scale, Phase 3 randomized controlled trials with pre-specified cardiovascular outcomes, consistent replication across diverse patient populations, and regulatory approval in multiple jurisdictions. The SELECT trial added landmark cardiovascular outcome data rarely seen in weight management pharmacotherapy.
Limitations & Uncertainty
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) affect a significant proportion of patients during dose titration and are a primary reason for discontinuation. Long-term safety data beyond the current trial windows (3-5 years) is still accumulating. Weight regain upon discontinuation is well-documented. Subcutaneous injection is required. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Evidence transparency: Evidence quality varies by molecule, population, and endpoint. Where data is limited or mixed, uncertainty is stated directly.
Risk, contraindications, interactions, and follow-up planning should be reviewed with a licensed clinician before initiating any GLP-1 therapy. This content is educational and does not replace individualized medical advice.
Back to: Molecule Discussion Guide | Clinical Sources | Evidence Methodology